Pricing Log in Create free account

Oculis Holding AG (OCS) vs REGENXBIO Inc. (RGNX)

Oculis Holding AG and REGENXBIO Inc. are both Biotechnology companies. Oculis Holding AG and REGENXBIO Inc. are of similar size ($472.7M and $456.8M). Oculis Holding AG grew revenue faster over the last twelve months: 65.8% against 12.0%. REGENXBIO Inc. has the higher net margin (−112.6% vs −6,870.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Oculis Holding AG leads on 8 and REGENXBIO Inc. on 8.

Valuation

Metric OCS RGNX Biotechnology median
P/E n/m n/m 8.50
P/S 303.32 2.10 9.71
P/B 1.61 5.10 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 108.92 1.53 9.21
Earnings yield (23.87%) (54.69%) (33.15%)
Free cash flow yield (18.51%) (68.21%) (25.50%)

Profitability

Metric OCS RGNX Biotechnology median
Gross margin 100.00% 86.38% 65.16%
Operating margin (7,383.66%) (94.08%) 0.00%
Net margin (6,870.05%) (112.58%) 0.00%
Free cash flow margin (5,525.64%) (143.09%) 0.00%
Return on equity (44.87%) (137.63%) (56.36%)
Return on assets (37.69%) (40.60%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric OCS RGNX Biotechnology median
Revenue growth (TTM) 65.83% 12.00% 6.02%
EPS growth (last fiscal year) 5.39% 18.08% 30.26%
Revenue growth, 5-year CAGR — 1.97% 9.41%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric OCS RGNX Biotechnology median
Debt to equity 0.01 0.00 0.00
Current ratio 8.35 2.86 4.72
Net debt to EBITDA 2.60 1.58 0.96

Dividend

Metric OCS RGNX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric OCS RGNX Biotechnology median
Market cap 456.82m 472.65m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack